ABSTRACT
Purpose:
Holmium-166 has emerged as a promising option for selective internal
radiotherapy (
SIRT) for hepatic
malignancies, but data on routine clinical use are lacking. The purpose of this study was to describe the
safety and
effectiveness of
Holmium-166
SIRT in real-world practice through retrospective
analysis of a multicenter
registry.
Methods:
Retrospective
analysis was conducted on
Holmium-166
SIRT procedures performed between July 15, 2019, and July 15, 2021, across seven European centers.
Treatment planning,
treatment realization and post-
treatment follow-up were conducted according to routine local practice.
Safety and
effectiveness data were extracted from the
patients'
health records. Primary endpoint
analysis was assessed for the entire study
population with separate
analysis for subgroups with
hepatocellular carcinoma, metastatic
colorectal cancer and
intrahepatic cholangiocarcinoma.
Results:
A total of 167
SIRT procedures in 146
patients (mean age 66 ± 11 years, 68%
male) were retrospectively evaluated. Most common
tumor entities were
hepatocellular carcinoma (n=55), metastatic
colorectal cancer (n=35),
intrahepatic cholangiocarcinoma (n=19) and metastatic
neuroendocrine tumors (n=10). Nine adverse events grade ≥ 3 according to Common Terminology Criteria for Adverse Events were recorded, including one fatal case of radioembolization-induced
liver disease. Response rates and median overall
survival for the above mentioned subgroups were comparable to results from previous
Holmium-166 trials as well as to results from
Yttrium-90
registries.
Conclusion:
This study confirms that the
safety and
effectiveness of
Holmium-166
SIRT derived from prospective trials also applies in routine clinical practice, reinforcing its potential as a viable
treatment option for primary and
secondary liver cancer.
